Cytiva’s 2025 Global Biopharma Index shows widening gaps across regions as talent shortages, regulatory strain, and uneven sustainability progress weigh on growth.
The New Jersey investment more than doubles Hovione’s U.S. spray drying capacity to support solubility enhancement and bioavailability in drug development.
The investment reportedly enhances solid-phase peptide synthesis and purification capacity to strengthen domestic production of active pharmaceutical ingredients.
The Swiss dermatology company plans to ramp up production of key brands including Nemluvio, Alastin and Cetaphil through U.S.-based contract manufacturing partners.
Learn about the role of environmental monitoring in a robust contamination control strategy to maintain product integrity and safeguard patient safety.
Explore proven alternatives to fetal bovine serum (FBS). Discover how donor bovine serum and other options can reduce cost and supply risks while maintaining performance in bioproductio...
While the plant was recently hit with the FDA’s most severe post-inspection classification, it is a facility that has been plagued with problems for several years.
Industry stakeholders who attended the annual Cell & Gene Meeting on the Mesa this week in Phoenix emphasized the positive, despite formidable challenges.
Since the start of his second term, President Trump has doubled, tripled, and quadrupled down on his threat to impose tariffs on pharmaceuticals. Is it just bluster?
Panelists at the 2025 Cell & Gene Meeting on the Mesa laid out the challenges and opportunities facing the industry as it looks to produce these therapies at scale.
Despite industry setbacks with adeno associated virus-based gene therapy programs, the issue is “largely overblown” for Repligen, contend Leerink Partners analysts.
The agency is reviewing clinical trials that involve sending U.S. patients’ living cells to China and other “hostile countries” for genetic engineering and return infusion.
With manufacturers under increasing pressure to reduce costs, enhance compliance, and accelerate production timelines for high quality drugs, they are increasing their investments...
Improve bioreactor performance, accelerate process development from benchtop to production, assess respiratory efficiency with continuous CO2 monitoring, eliminate potential interferenc...
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
Discover the latest contract manufacturing key trends for the life science industry, including compliance, digital transformation and more. Don't let your organization fall behind...
As the life sciences sector evolves with personalized medicine, biologics, and digitalization, manufacturers must innovate, invest in advanced tech, and adopt agile manufacturing...
This episode of Off Script: A Pharma Manufacturing Podcast features a conversation with Jana Falkenberg, senior legal counsel and corporate compliance officer at Vetter Pharma...
CEO Pascal Soriot announced the deal with President Trump on Friday, noting that it includes a three-year exemption from U.S. tariffs for AstraZeneca’s products.
Designed for the review of abbreviated new drug applications, the program is meant to strengthen the domestic pharmaceutical supply chain in the United States.
The deadline for imposing a 100% tariff on branded pharmaceuticals passed, without going into effect, as the Trump administration looks to strike deals to lower drug prices.
The industry’s inability to make products efficiently and at scale is due to the complexity of the supply chain, panelists said at the Cell & Gene Meeting on the Mesa.
Read more about how WarmMark QR addresses today’s common cold chain monitoring challenges through an innovative combination of visual and digital tracking.